Alkem announces 600-700 camps under ‘Reliever Free India’ Initiative

In recognition of World Asthma Day 2024, Alkem Laboratories (Alkem) announced 600 to 700 camps across India, collaborating with nearly 100 hospitals in tier-1 and tier-2 cities under its “Reliever Free India” initiative. This nationwide initiative was launched in 2023 with an aim to revolutionise asthma management by advocating for a shift in focus from reliance on reliever medications to the importance of controller medications. Reliever medications provide quick relief during asthma symptoms by opening up the airways. Controller medications are taken regularly to prevent asthma symptoms and reduce inflammation in the airways. After a successful first year, Alkem is intensifying the campaign in its second year.

Asthma affects approximately 262 million people globally, causing recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. Despite advancements in medical treatment, asthma remains a significant challenge for patients and healthcare providers alike. 

Alkem spokesperson said, “We’ve engaged with over 500 camps since the start of our campaign. This year, we’re expanding our commitment by organising at least 600 camps and clinics to raise awareness about asthma and its management. Our goal is to empower patients with the knowledge they need to take control of their health.”

The “Reliever Free India” campaign emphasises the importance of using controller medications for optimal asthma management. While reliever medications offer immediate relief during asthma attacks, they do not address the underlying inflammation that contributes to the condition’s chronic nature. Over-reliance on relievers can lead to poor long-term outcomes and increased risk of exacerbations. Through this campaign, Alkem seeks to educate patients, healthcare professionals, and the general public about the benefits of controller medications in preventing asthma symptoms and reducing the need for rescue medication.